{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T09:12:51Z","timestamp":1692004371314},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00393-020-00848-6","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T13:02:38Z","timestamp":1596805358000},"page":"660-668","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lokale und systemische Leichtkettenamyloidosen bei Patienten mit rheumatologischen Erkrankungen"],"prefix":"10.1007","volume":"79","author":[{"given":"K.","family":"Veelken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Hegenbart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. O.","family":"Sch\u00f6nland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,7]]},"reference":[{"key":"848_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0961203307079045","volume":"16","author":"YM Ali","year":"2007","unstructured":"Ali\u00a0YM, Urowitz\u00a0MB, Ibanez\u00a0D et\u00a0al (2007) Monoclonal gammopathy in systemic lupus erythematosus. Lupus 16:426\u2013429","journal-title":"Lupus"},{"key":"848_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-020-00848-6","author":"M Basset","year":"2020","unstructured":"Basset\u00a0M, Hummedah\u00a0K, Kimmich\u00a0C et\u00a0al (2020) Localized immunoglobulin light chain amyloidosis: novel insights including prognostic factors for local progression. Am J Hematol. https:\/\/doi.org\/10.1007\/s00393-020-00848-6","journal-title":"Am J Hematol"},{"key":"848_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3324\/haematol.11687","volume":"93","author":"T Bochtler","year":"2008","unstructured":"Bochtler\u00a0T, Hegenbart\u00a0U, Heiss\u00a0C et al (2008) Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 93:459\u2013462","journal-title":"Haematologica"},{"key":"848_CR4","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/ard.60.7.694","volume":"60","author":"I Delevaux","year":"2001","unstructured":"Delevaux\u00a0I, Andre\u00a0M, Amoura\u00a0Z et\u00a0al (2001) Concomitant diagnosis of primary Sjogren\u2019s syndrome and systemic AL amyloidosis. Ann Rheum Dis 60:694\u2013695","journal-title":"Ann Rheum Dis"},{"key":"848_CR5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/rcr2.104","volume":"3","author":"CM Ellender","year":"2015","unstructured":"Ellender\u00a0CM, Mclean\u00a0C, Williams\u00a0TJ et\u00a0al (2015) Autoimmune disease leading to pulmonary AL amyloidosis and pulmonary hypertension. Respirol Case Rep 3:78\u201381","journal-title":"Respirol Case Rep"},{"key":"848_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1309\/TR4LGLVRJKAMV5QT","volume":"121","author":"MA Gertz","year":"2004","unstructured":"Gertz\u00a0MA (2004) The classification and typing of amyloid deposits. Am J Clin Pathol 121:787\u2013789","journal-title":"Am J Clin Pathol"},{"key":"848_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-018-0080-9","volume":"8","author":"MA Gertz","year":"2018","unstructured":"Gertz\u00a0MA (2018) Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer\u00a0J 8:44","journal-title":"Blood Cancer J"},{"key":"848_CR8","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ajh.25149","volume":"93","author":"MA Gertz","year":"2018","unstructured":"Gertz\u00a0MA (2018) Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol 93:1169\u20131180","journal-title":"Am J Hematol"},{"key":"848_CR9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000276907","volume":"59","author":"H Haraguchi","year":"1997","unstructured":"Haraguchi\u00a0H, Ohashi\u00a0K, Yamada\u00a0M et\u00a0al (1997) Primary localized nodular tongue amyloidosis associated with Sjogren\u2019s syndrome. Orl J Otorhinolaryngol Relat Spec 59:60\u201363","journal-title":"Orl J Otorhinolaryngol Relat Spec"},{"key":"848_CR10","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/00365520410008105","volume":"39","author":"I Janczewska","year":"2004","unstructured":"Janczewska\u00a0I, Mejhert\u00a0M, Hast\u00a0R et al (2004) Primary AL-amyloidosis, ulcerative colitis and collagenous colitis in a\u00a057-year-old woman: a\u00a0case study. Scand J Gastroenterol 39:1306\u20131309","journal-title":"Scand J Gastroenterol"},{"key":"848_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/jcp.56.1.74","volume":"56","author":"M Kambouchner","year":"2003","unstructured":"Kambouchner\u00a0M, Godmer\u00a0P, Guillevin\u00a0L et\u00a0al (2003) Low grade marginal zone B cell lymphoma of the breast associated with localised amyloidosis and corpora amylacea in a\u00a0woman with long standing primary Sjogren\u2019s syndrome. J\u00a0Clin Pathol 56:74\u201377","journal-title":"J Clin Pathol"},{"key":"848_CR12","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.52300","author":"P Kazman","year":"2020","unstructured":"Kazman\u00a0P, Vielberg\u00a0MT, Pulido Cendales\u00a0MD et\u00a0al (2020) Fatal amyloid formation in a\u00a0patient\u2019s antibody light chain is caused by a\u00a0single point mutation. eLife. https:\/\/doi.org\/10.7554\/eLife.52300","journal-title":"eLife"},{"key":"848_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/00000478-200606000-00002","volume":"30","author":"A Kebbel","year":"2006","unstructured":"Kebbel\u00a0A, Rocken\u00a0C (2006) Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol 30:673\u2013683","journal-title":"Am J Surg Pathol"},{"key":"848_CR14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.mayocp.2017.02.016","volume":"92","author":"TV Kourelis","year":"2017","unstructured":"Kourelis\u00a0TV, Kyle\u00a0RA, Dingli\u00a0D et\u00a0al (2017) Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo clinic experience. Mayo Clin Proc 92:908\u2013917","journal-title":"Mayo Clin Proc"},{"key":"848_CR15","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"RA Kyle","year":"1992","unstructured":"Kyle\u00a0RA, Linos\u00a0A, Beard\u00a0CM et\u00a0al (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79:1817\u20131822","journal-title":"Blood"},{"key":"848_CR16","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle\u00a0RA, Therneau\u00a0TM, Rajkumar\u00a0SV et\u00a0al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N\u00a0Engl J Med 354:1362\u20131369","journal-title":"N Engl J Med"},{"key":"848_CR17","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa013354","volume":"346","author":"HJ Lachmann","year":"2002","unstructured":"Lachmann\u00a0HJ, Booth\u00a0DR, Booth\u00a0SE et\u00a0al (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N\u00a0Engl J Med 346:1786\u20131791","journal-title":"N Engl J Med"},{"key":"848_CR18","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1016\/S2352-3026(15)00068-X","volume":"2","author":"S Mahmood","year":"2015","unstructured":"Mahmood\u00a0S, Bridoux\u00a0F, Venner\u00a0CP et al (2015) Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a\u00a0long-term observational study. Lancet Haematol 2:e241\u2013250","journal-title":"Lancet Haematol"},{"key":"848_CR19","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/art.23617","volume":"58","author":"JM Meijer","year":"2008","unstructured":"Meijer\u00a0JM, Schonland\u00a0SO, Palladini\u00a0G et\u00a0al (2008) Sjogren\u2019s syndrome and localized nodular cutaneous amyloidosis: coincidence or a\u00a0distinct clinical entity? Arthritis Rheum 58:1992\u20131999","journal-title":"Arthritis Rheum"},{"key":"848_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","volume":"2017","author":"G Merlini","year":"2017","unstructured":"Merlini\u00a0G (2017) AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program 2017:1\u201312","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"848_CR21","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini\u00a0G, Bellotti\u00a0V (2003) Molecular mechanisms of amyloidosis. N\u00a0Engl J Med 349:583\u2013596","journal-title":"N Engl J Med"},{"key":"848_CR22","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini\u00a0G, Dispenzieri\u00a0A, Gertz\u00a0MA et\u00a0al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J\u00a0Clin Oncol 30:4541\u20134549","journal-title":"J Clin Oncol"},{"key":"848_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","volume":"99","author":"G Palladini","year":"2014","unstructured":"Palladini\u00a0G, Milani\u00a0P, Foli\u00a0A et al (2014) Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a\u00a0risk-adapted approach. Haematologica 99:743\u2013750","journal-title":"Haematologica"},{"key":"848_CR24","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1378\/chest.130.5.1489","volume":"130","author":"JG Parambil","year":"2006","unstructured":"Parambil\u00a0JG, Myers\u00a0JL, Lindell\u00a0RM et\u00a0al (2006) Interstitial lung disease in primary Sjogren syndrome. Chest 130:1489\u20131495","journal-title":"Chest"},{"key":"848_CR25","first-page":"12","volume":"39","author":"A Raposo","year":"2014","unstructured":"Raposo\u00a0A, Peixoto\u00a0D, Bogas\u00a0M (2014) Monoclonal gammopathy and rheumatic diseases. Acta Reumatol Port 39:12\u201318","journal-title":"Acta Reumatol Port"},{"key":"848_CR26","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1182\/blood-2014-04-568329","volume":"124","author":"DE Reece","year":"2014","unstructured":"Reece\u00a0DE, Hegenbart\u00a0U, Sanchorawala\u00a0V et al (2014) Long-term follow-up from a\u00a0phase 1\/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood 124:2498\u20132506","journal-title":"Blood"},{"key":"848_CR27","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2559.1996.tb01416.x","volume":"29","author":"C Rocken","year":"1996","unstructured":"Rocken\u00a0C, Schwotzer\u00a0EB, Linke\u00a0RP et\u00a0al (1996) The classification of amyloid deposits in clinicopathological practice. Histopathology 29:325\u2013335","journal-title":"Histopathology"},{"key":"848_CR28","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","volume":"119","author":"SO Schonland","year":"2012","unstructured":"Schonland\u00a0SO, Hegenbart\u00a0U, Bochtler\u00a0T et\u00a0al (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a\u00a0systematic investigation of 117 patients. Blood 119:488\u2013493","journal-title":"Blood"},{"key":"848_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","volume":"23","author":"JD Sipe","year":"2016","unstructured":"Sipe\u00a0JD, Benson\u00a0MD, Buxbaum\u00a0JN et\u00a0al (2016) Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23:209\u2013213","journal-title":"Amyloid"},{"key":"848_CR30","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/j.ejca.2006.04.021","volume":"42","author":"KC Soderberg","year":"2006","unstructured":"Soderberg\u00a0KC, Jonsson\u00a0F, Winqvist\u00a0O et al (2006) Autoimmune diseases, asthma and risk of haematological malignancies: a\u00a0nationwide case-control study in Sweden. Eur J Cancer 42:3028\u20133033","journal-title":"Eur J Cancer"},{"key":"848_CR31","first-page":"265","volume":"33","author":"SL Strobel","year":"2003","unstructured":"Strobel\u00a0SL (2003) Transient paraproteinemia: an intriguing immunological anomaly. Ann Clin Lab Sci 33:265\u2013270","journal-title":"Ann Clin Lab Sci"},{"key":"848_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00428-019-02527-7","volume":"474","author":"C Stuhlmann-Laeisz","year":"2019","unstructured":"Stuhlmann-Laeisz\u00a0C, Schonland\u00a0SO, Hegenbart\u00a0U et al (2019) AL amyloidosis with a\u00a0localized B cell neoplasia. Virchows Arch 474:353\u2013363","journal-title":"Virchows Arch"},{"key":"848_CR33","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1100\/tsw.2011.64","volume":"11","author":"JC Van Der Hilst","year":"2011","unstructured":"Van Der Hilst\u00a0JC (2011) Recent insights into the pathogenesis of type AA amyloidosis. ScientificWorldJournal 11:641\u2013650","journal-title":"ScientificWorldJournal"},{"key":"848_CR34","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clim.2017.05.002","volume":"182","author":"GM Verstappen","year":"2017","unstructured":"Verstappen\u00a0GM, Van Nimwegen\u00a0JF, Vissink\u00a0A et\u00a0al (2017) The value of rituximab treatment in primary Sjogren\u2019s syndrome. Clin Immunol 182:62\u201371","journal-title":"Clin Immunol"},{"key":"848_CR35","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali\u00a0C, Bombardieri\u00a0S, Jonsson\u00a0R et al (2002) Classification criteria for Sjogren\u2019s syndrome: a\u00a0revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554\u2013558","journal-title":"Ann Rheum Dis"},{"key":"848_CR36","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar\u00a0AD, Schonland\u00a0SO, Kastritis\u00a0E et\u00a0al (2013) A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood 121:3420\u20133427","journal-title":"Blood"},{"key":"848_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/03009734.2012.654861","volume":"117","author":"P Westermark","year":"2012","unstructured":"Westermark\u00a0P (2012) Localized AL amyloidosis: a\u00a0suicidal neoplasm? Ups J Med Sci 117:244\u2013250","journal-title":"Ups J Med Sci"},{"key":"848_CR38","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s10067-018-4064-8","volume":"37","author":"Y Yang","year":"2018","unstructured":"Yang\u00a0Y, Chen\u00a0L, Jia\u00a0Y et\u00a0al (2018) Monoclonal gammopathy in rheumatic diseases. Clin Rheumatol 37:1751\u20131762","journal-title":"Clin Rheumatol"},{"key":"848_CR39","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1346-8138.2005.tb00728.x","volume":"32","author":"K Yoneyama","year":"2005","unstructured":"Yoneyama\u00a0K, Tochigi\u00a0N, Oikawa\u00a0A et\u00a0al (2005) Primary localized cutaneous nodular amyloidosis in a\u00a0patient with Sjogren\u2019s syndrome: a\u00a0review of the literature. J\u00a0Dermatol 32:120\u2013123","journal-title":"J Dermatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00848-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00848-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T23:26:11Z","timestamp":1628292371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00848-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["848"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00848-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]},"assertion":[{"value":"7 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Veelken gibt an, dass kein Interessenkonflikt besteht. U.\u00a0Hegenbart erhielt Forschungsunterst\u00fctzung von Janssen sowie Vortragshonorare und Unterst\u00fctzung von Kongressteilnahmen von Janssen, Prothena, Alnylam, Akcea und Pfizer, N.\u00a0Blank erhielt Forschungsunterst\u00fctzung von den Firmen SOBI und Novartis sowie Vortragshonorare und Unterst\u00fctzung von Kongressteilnahmen von SOBI, Novartis, Roche, MSD, Abbott, Pfizer, Boehringer-Ingelheim, Actelion und UCB. S.O.\u00a0Sch\u00f6nland erhielt Forschungsunterst\u00fctzung von Sanofi und Janssen sowie Unterst\u00fctzung zu Kongressteilnahmen von Medac, Sanofi, Janssen und Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenskonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenskonflikt"}}]}}